Viva Biotech Successfully Held 2021 Partnership Summit -- Novel Drug 2021, the Persistence and Transformation of Start-up Founders
SHANGHAI, March 10, 2021 /PRNewswire/ -- March 2nd-6th, 2021, Viva Biotech successfully hosted the 2021 Partnership Summit. Over 300 attendees joined the Summit, including representatives from global investment institutions, R&D heads from pharmaceutical companies, and business development leader...
Viva Biotech Announced 2020 Interim Results
Financial Highlights for the 6 months ended June 30, 2020 * Revenue amounted to RMB197.6 million, representing a YOY increase of 38.9% * Gross profit amounted to RMB100.1 million, representing a YOY increase of 39.2%, with Gross profit margin of 50.7% * Adjusted net profit rose to RMB123.7 m...
Viva Biotech and Schrödinger Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets
SHANGHAI and NEWYORK, July 28, 2020 /PRNewswire/ -- Viva Biotech Holdings (1873.HK) and Schrödinger, Inc. (Nasdaq: SDGR) today announced a strategic collaboration to expand the reach of structure-based drug discovery by generatingde novo crystal structures of high-value targets. Under the terms ...
Viva Biotech Announced 2019 Annual Results
Financial Highlights For the year ended December 31, 2019 * Revenue amounted to approximately RMB323.1 million, representing a significant YOY increase of 53.9% from approximatelyRMB210.0 million in the same period last year. * Gross profit amounted to approximately RMB155.9 million, represe...
Viva Biotech Announces 2019 Interim Results
Financial Highlights * Revenue grew significantly by 83.9% YoY from RMB77.4 million to approximatelyRMB142.3 million. * Gross profit recorded approximately RMB71.9 million, growing significantly by 70.0% fromRMB42.3 million. * Net profit excluding extraordinary profit or loss increased sig...
